INVO Bioscience, Inc.
INVO
$1.72
-$0.379-18.05%
| Weiss Ratings | INVO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | INVO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | INVO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.08 | |||
| Price History | INVO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 145.86% | |||
| 30-Day Total Return | 118.12% | |||
| 60-Day Total Return | 122.78% | |||
| 90-Day Total Return | 123.51% | |||
| Year to Date Total Return | 34.45% | |||
| 1-Year Total Return | 166.41% | |||
| 2-Year Total Return | -93.06% | |||
| 3-Year Total Return | -97.83% | |||
| 5-Year Total Return | -99.07% | |||
| 52-Week High % Change | -64.57% | |||
| 52-Week Low % Change | 148.00% | |||
| Price | INVO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $3.50 | |||
| 52-Week Low Price | $0.50 | |||
| 52-Week Low Price (Date) | Oct 19, 2023 | |||
| 52-Week High Price (Date) | Apr 17, 2024 | |||
| Valuation | INVO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 4.84M | |||
| Enterprise Value | 16.78M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.38 | |||
| Earnings Per Share Growth | -85.01% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.78 | |||
| Price/Book (Q) | -0.78 | |||
| Enterprise Value/Revenue (TTM) | 2.91 | |||
| Price | $1.72 | |||
| Enterprise Value/EBITDA (TTM) | -3.63 | |||
| Enterprise Value/EBIT | -3.20 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | INVO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 3.61M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | INVO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 978 878 9505 | |||
| Address | 5582 Broadcast Court Sarasota, FL 34240 | |||
| Website | www.invobioscience.com | |||
| Country | United States | |||
| Year Founded | 2007 | |||
| Profitability | INVO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -90.89% | |||
| Profit Margin | -122.79% | |||
| Management Effectiveness | INVO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -26.57% | |||
| Return on Equity | -- | |||
| Income Statement | INVO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 5.77M | |||
| Total Revenue (TTM) | 5.77M | |||
| Revenue Per Share | $1.60 | |||
| Gross Profit (TTM) | 2.59M | |||
| EBITDA (TTM) | -4.62M | |||
| EBIT (TTM) | -5.24M | |||
| Net Income (TTM) | -7.08M | |||
| Net Income Avl. to Common (TTM) | -7.08M | |||
| Total Revenue Growth (Q YOY) | 481.39% | |||
| Earnings Growth (Q YOY) | -0.21% | |||
| EPS Diluted (TTM) | -2.38 | |||
| EPS Diluted Growth (Q YOY) | 79.67% | |||
| Balance Sheet | INVO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 942.90K | |||
| Cash Per Share (Q) | $0.26 | |||
| Total Current Assets (Q) | 2.40M | |||
| Total Preferred Equity (Q) | 7.51 | |||
| Total Equity (Q) | 1.36M | |||
| Current Ratio (Q) | 0.300 | |||
| Book Value Per Share (Q) | -$1.59 | |||
| Total Assets (Q) | 18.03M | |||
| Total Current Liabilities (Q) | 7.99M | |||
| Total Debt (Q) | 5.38M | |||
| Total Liabilities (Q) | 16.67M | |||
| Total Common Equity (Q) | -6.14M | |||
| Cash Flow | INVO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -2.25M | |||
| Cash from Financing (TTM) | 6.76M | |||
| Net Change in Cash (TTM) | 830.50K | |||
| Levered Free Cash Flow (TTM) | 1.49M | |||
| Cash from Operations (TTM) | -3.68M | |||
